Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus

NANot yet recruitingINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Ischemic StrokeType 2 Diabetes
Interventions
DRUG

Urinary Kallidinogenase for injection

The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days

OTHER

Placebo

The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.

Trial Locations (1)

510080

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER